Tarceva recommended for maintenance use in NSCLC in EU
This article was originally published in Scrip
Executive Summary
Roche's EGFR-targeted drug Tarceva (erlotinib) has been recommended for approval by the EU's CHMP for the maintenance treatment of advanced non-small cell lung cancer (NSCLC) that has not progressed on standard platinum-based chemotherapy.